Research never stops


In July 2011, Evotec AG and UCB entered into a three year integrated drug discovery collaboration to identify small molecule modulators of priority biological targets, selected by UCB, involved in CNS disorders.

As part of the collaboration, Evotec will apply its integrated drug discovery expertise and technologies to identify interesting small molecules against the selected targets. The molecules will be further optimised and progressed through lead optimisation to a pre-clinical candidate.

In October 2011, Evotec AG and UCB entered into a second multiyear, multi-target integrated drug discovery collaboration in the field of immunology. In October 2013, Evotec announced that the first two milestones were met in this immunology alliance with UCB. The milestones were achieved upon the progression of certain projects into hit-to-lead and into lead optimisation.